Select Page

IG Usage in 2021 and Forecast to 2030 in the United States

 

AN ANALYSIS OF THE 2021 United States INTRAVENOUS AND SUBCUTANEOUS IMMUNOGLOBULIN MARKET (IVIG & SCIG) AND FORECAST TO THE YEAR 2030

In recent years, the demand for IG has grown at >8% annually in the U.S. due to the addition of new patients treated, new medical indications, higher dosage, longer life expectancy, weight gains and other factors while prices have increased moderately. At the same time, the growing demand in emerging markets has also contributed to the market expansion, putting pressure on manufacturing and plasma collections. Today, IG remains the undisputable driver of the global plasma proteins market, from plasma collections to fractionation capacity expansion and financial health of the companies.

Combining primary and secondary research, this study describe the United States 2021 IG market by three metrics: By all indications, by route of administration (IVIG & SCIG) and by site of care. It then uses all this information and the view of experts to provide a yearly forecast of the demand to 2030 in grams and in dollars. It also provides a breakdown of IG use in grams by medical indication for each of these years from 2021 through 2030.

The report is a 210 page report which extensively covers current use of all uses of IG across diseases and makes extensive predictions about how each market will develop given novel competition and reactions by plasma companies in the coming years. 

Table of Contents

Executive Summary

1. Introduction

2. Methodology & Assumptions

2.1 Research Resources

2.2 Market Analysis

2.3 Forecasting the Period 2021 to 2030

2.4 Selection of Diseases/Disease Categories

2.5 Comorbidities

3. 2021 Market Analysis

3.1 Total IG Market – Volume and Growth 2015-2021

3.2 IVIG and SCIG Market by Disease

3.3 Site of Care Analysis

3.4 IG Market by Medical Specialty

3.5 Average IG Usage per Patient & Number of Patients on each Therapy

3.6 Discussion of Key Diseases in 2021

3.6.1-3.6.13 Primary Immunodeficiency Diseases (PID), Chronic inflammatory demyelinating polyneuropathy (CIDP), Thrombocytopenia/ITP, Myasthenia gravis (Acute & Chronic), Transplant, Multifocal Motor Neuropathy (MMN), Neuropathy, SID/CLL, Dermatomyositis, GBS, Stiff Person Syndrome, Encephalitis

3.6.14 All Other Conditions

3.7 2018-2021 Average Growth and Contribution to Growth of Top Diseases

4. 2025 Forecast Methodology and Assumptions

4.1 Overall Forecast Assumptions

4.2 Assumptions about Competition in Key Diseases (FcRn and others)


5. 2030 Forecast Market Analysis

5.1 Total IG Market – Volume and Growth 2021-2030

5.2 By IVIG and SCIG Markets – Volume and Growth 2021-2030

5.3 Forecast of IG Market by Medical Specialty to 2030

5.4 Discussion of Key Diseases from 2021 to 2030

5.4.1-5.4.13 Primary Immunodeficiency Diseases (PID), Chronic inflammatory demyelinating polyneuropathy (CIDP), Thrombocytopenia/ITP, Myasthenia gravis (Acute & Chronic), Transplant, Multifocal Motor Neuropathy (MMN), Neuropathy, SID/CLL, Dermatomyositis, GBS, Stiff Person Syndrome

5.4.14 All Other Conditions

5.5 2021-2030 Average Growth and Contribution to Growth of Top Diseases

5.6 US IG Market by Dollar Value from 2021 to 2030